201 related articles for article (PubMed ID: 18614586)
21. Palliative chemotherapy for advanced gastric cancer.
Wöhrer SS; Raderer M; Hejna M
Ann Oncol; 2004 Nov; 15(11):1585-95. PubMed ID: 15520058
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.
Rivera F; Massutí B; Salcedo M; Sastre J; Martínez Galán J; Valladares-Ayerbes M; Serrano R; García de Paredes ML; Manzano JL; Galán M; Alsina M; Yuste Izquierdo AL; López C; Díaz-Rubio E; Conde V; Reboredo M; Cano MT; Pachón V; Aranda E
Cancer Chemother Pharmacol; 2015 Feb; 75(2):319-24. PubMed ID: 25491381
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
24. Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy.
Goto A; Sukawa Y; Igarashi H; Onodera K; Aoki Y; Suzuki K; Yonezawa K; Yawata A; Kobayashi T; Kaneto H; Shimizu H; Wakasugi H; Matsunaga Y; Itoh M; Okuda H; Arimura Y; Shinomura Y
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1461-6. PubMed ID: 21945893
[TBL] [Abstract][Full Text] [Related]
25. [Latest progress on chemotherapy for advanced gastric cancer].
Tahara M; Ohtsu A
Gan To Kagaku Ryoho; 2000 Nov; 27(13):2048-58. PubMed ID: 11103236
[TBL] [Abstract][Full Text] [Related]
26. Medical treatment for advanced gastroesophageal adenocarcinoma.
Cen P; Ajani JA
Curr Opin Gastroenterol; 2007 Nov; 23(6):631-5. PubMed ID: 17906439
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.
Iizumi S; Takashima A; Narita Y; Tajika M; Muro K; Kawai S; Yasui H; Matsushima T; Takahari D; Nagashima K; Boku N
Cancer Chemother Pharmacol; 2017 Sep; 80(3):575-582. PubMed ID: 28730292
[TBL] [Abstract][Full Text] [Related]
28. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
Ocvirk J; Reberšek M; Skof E; Hlebanja Z; Boc M
Am J Clin Oncol; 2012 Jun; 35(3):237-41. PubMed ID: 21399488
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.
Wu B; Li T; Cai J; Xu Y; Zhao G
BMC Cancer; 2014 Dec; 14():984. PubMed ID: 25526802
[TBL] [Abstract][Full Text] [Related]
30. New advances in the treatment of gastric cancer.
Ilson DH
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-29-33. PubMed ID: 23570096
[No Abstract] [Full Text] [Related]
31. S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
He MM; Wu WJ; Wang F; Wang ZQ; Zhang DS; Luo HY; Qiu MZ; Wang FH; Ren C; Zeng ZL; Xu RH
PLoS One; 2013; 8(12):e82798. PubMed ID: 24349363
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy for colorectal cancer.
Goyle S; Maraveyas A
Dig Surg; 2005; 22(6):401-14. PubMed ID: 16479107
[TBL] [Abstract][Full Text] [Related]
33. Oral treatment for gastric cancer: new choices, better choices?
Cascinu S
Lancet Oncol; 2008 Mar; 9(3):188-9. PubMed ID: 18308239
[No Abstract] [Full Text] [Related]
34. Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract.
Ilhan-Mutlu A; Preusser M; Schoppmann SF; Asari R; Ba-Ssalamah A; Schwameis K; Pluschnig U; Birner P; Püspök A; Zacherl J; Hejna M
Anticancer Res; 2013 Aug; 33(8):3455-9. PubMed ID: 23898119
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy for advanced gastric cancer.
Wagner AD; Unverzagt S; Grothe W; Kleber G; Grothey A; Haerting J; Fleig WE
Cochrane Database Syst Rev; 2010 Mar; (3):CD004064. PubMed ID: 20238327
[TBL] [Abstract][Full Text] [Related]
36. Tegafur + gimeracil + oteracil. Just another fluorouracil precursor.
Prescrire Int; 2013 May; 22(138):122. PubMed ID: 23819172
[TBL] [Abstract][Full Text] [Related]
37. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
[TBL] [Abstract][Full Text] [Related]
38. Future treatment options with capecitabine in solid tumours.
Wilke H
Eur J Cancer; 2002 Feb; 38 Suppl 2():21-5. PubMed ID: 11841932
[TBL] [Abstract][Full Text] [Related]
39. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers.
Ajani J
Cancer; 2006 Jul; 107(2):221-31. PubMed ID: 16770784
[TBL] [Abstract][Full Text] [Related]
40. Treatment of advanced disease and new drugs.
Frustaci S; Buonadonna A; La Mura N; Berretta M; De Paoli A
Suppl Tumori; 2003; 2(5):S48-50. PubMed ID: 12914391
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]